Passadakis P, Thodis E, Vargemezis V, Oreopoulos D
Department of Nephrology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Clin Nephrol. 2001 Oct;56(4):257-70.
Several clinical studies have evaluated the factors that affect survival rates and compared outcomes between CAPD and HD in diabetic patients. However, only a small number of diabetic PD patients have been followed for over 5 years, largely because of coexisting, far-advanced, target organ damage at the initiation of dialysis and its progression during the course of dialysis, the presence of various comorbid conditions at the start of dialysis and finally, the limitations of long-term PD. Among the various modes of renal replacement, many clinicians have favored continuous ambulatory peritoneal dialysis (CAPD) for the management of diabetic patients for several reasons. However, survival of diabetic patients undergoing peritoneal dialysis (PD) and hemodialysis (HD) is probably similar, while diabetics on CAPD have a lower actuarial survival and technique success rates than non-diabetic patients of comparable age. This paper reviews the literature and our experience concerning the long-term survival on peritoneal dialysis of diabetic patients with ESRD.
多项临床研究评估了影响生存率的因素，并比较了糖尿病患者腹膜透析（CAPD）和血液透析（HD）的治疗结果。然而，仅有少数糖尿病腹膜透析患者被随访超过5年，主要原因是透析开始时存在并存的、进展严重的靶器官损害及其在透析过程中的进展、透析开始时存在各种合并症，以及长期腹膜透析的局限性。在各种肾脏替代模式中，许多临床医生因多种原因倾向于采用持续非卧床腹膜透析（CAPD）治疗糖尿病患者。然而，接受腹膜透析（PD）和血液透析（HD）的糖尿病患者的生存率可能相似，而接受CAPD治疗的糖尿病患者的精算生存率和技术成功率低于年龄相仿的非糖尿病患者。本文回顾了有关终末期肾病（ESRD）糖尿病患者腹膜透析长期生存的文献及我们的经验。
